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Background and Objectives. Acute promyelocytic
leukemia is characterized by the chromosomal
translocation t(15;17) which yields the fusion prod-
uct PML/RAR. All-trans retinoic acid probably
induces differentiation of atypical promyelocytes and
clinical remission in APL patients by binding to the
ligand binding domain (LBD) of the RAR portion of
the PML-RAR chimeric protein. Structural alter-
ations of the LBD of the PML/RAR have been
revealed in ATRA resistant APL cell lines and in a few
APL patients with acquired clinical resistance to
ATRA therapy. Two APL relapsed patients with clini-
cal resistance to ATRA therapy were evaluated for
the presence of nucleotide mutations in the LBD of
PML/RAR gene and then treated with arsenic tri-
oxide (As2O3).
Design and Methods. DNA fragments from the LBD of
the PML/RAR chimeric transcript were obtained by
reverse-transcribed polymerase chain reaction. Direct
sequencing was performed by an unambiguous bi-
directional automatic analysis. Samples representa-
tive of APL onset and relapse were analyzed from
both patients.
Results. In both patients, at the ATRA resistant
relapse, a missense point mutation in the LBD of the
PML/RAR gene was found. The mutations, absent
at APL onset, led to an Arg272Gln and to an
Arg276Trp amino acid substitution, according to the
sequence of the RAR protein. Both patients had
complete clinical and hematologic remission after
treatment with As2O3.
Interpretation and Conclusions. LBD missense muta-
tions appear to be a significant mechanism of
acquired ATRA-resistance in vivo, closely related to
clinical APL relapse. The two cases reported here
provide the first in vivo evidence of APL relapsed
patients, who have become ATRA resistant for mol-
ecular reasons, being sensitive to arsenic trioxide.
©1999, Ferrata Storti Foundation
Key words: acute promyelocytic leukemia, PML/RAR, ATRA-
resistance, missense point mutations, arsenic trioxide
The chromosomal translocation t(15;17), char-acteristic of acute promyelocytic leukemia(APL), involves the retinoic acid receptor-
(RAR) gene on chromosome 17 and the PML gene,
a putative transcription factor, on chromosome 15,
generating the PML/RAR chimeric gene.1-3 The
resulting PML/RAR chimeric protein is crucial to
the pathogenesis of APL.4
Moreover, APL has the unique characteristic of
responding in vitro and in vivo to differentiating thera-
py with all-trans retinoic acid (ATRA).5,6 The
PML/RAR protein retains the majority of the func-
tional domains of the RAR gene, in particular the
DNA- and the ligand-binding domain (LBD), main-
taining the ability to bind ATRA and activate tran-
scription.7-9 ATRA used as single agent in APL therapy
induces clinical remission in the great majority of
patients. Nevertheless, acquired clinical ATRA resis-
tance appears within a few months of treatment and
relapse occurs in almost all.10 For this reason, modern
treatment of APL combines ATRA with cytotoxic
chemotherapy, obtaining long remission in the major-
ity of patients.11,12 However, relapse still occurs in
about 20-30% of patients. In these patients clinical
ATRA resistance is often present. Several mechanisms
have been postulated to explain this clinical ATRA
resistance, including pharmacokinetic reasons13 and
an increase in the cellular retinoic acid binding protein
(CRABP) or multidrug-resistance (MDR) gene prod-
ucts.14,15 Moreover, APL cells from clinically ATRA-
resistant patients often exhibit ATRA-resistance or
decreased sensitivity in vitro, suggesting cellular mech-
anisms leading to the selection of ATRA resistant APL
subclones, in the presence of pharmacological con-
centrations of ATRA.14 A point mutation in the LBD
sequence, abolishing the ATRA binding activity of the
PML/RAR, has been detected in an ATRA-resistant
NB4 subclone,16 suggesting that similar alterations
might be the cause of ATRA resistance in vivo. Recent-
ly, two reports17,18 demonstrated the presence of such
mutations in 2 and 3 APL relapsed ATRA-resistant
patients.
Here we report the presence of mutations in the
LBD of PML/RAR gene in another two APL relapsed
ATRA-resistant patients, who were subsequently
shown to be clearly sensitive to As2O3 treatment.
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Design and Methods
Bone marrow aspirates were obtained from two
patients with APL. Patient #1 was referred to the Hema-
tology Division, Oncology Department, University of
Pisa and patient #2 to the Hematology Division, Depart-
ment of Medical Sciences of the University of Modena
and Reggio Emilia, Italy. Total RNA was extracted from
Lymphoprep (Nycomed Pharma AS, Majorstu, Norway)
isolated-mononuclear cells by a guanidinium thio-
cyanate-phenol-chloroform method.19,20
cDNA was synthesized using 1.5 µg of total RNA in
a 30 µL reaction mixture using 400 U of M-MLV reverse
transcriptase (GibcoBRL, Gaithersburg, MD, USA), 20
U of RNAsin (Roche Diagnostics, Mannheim, Ger-
many), 1 µg of oligo-dT10 primer (Roche Diagnostics,
Mannheim, Germany) in 50 mmol/L Tris-HCl, pH 8.3,
60 mmol/L KCl, 3 mmol/L MgCl2, 10 mmol/L DTT,
0.5 mmol/L dNTPs at 42°C for 1 hour followed by 3
minutes at 95°C. Five microliters of cDNA products
were used in the further PCR reactions. The presence
of the chimeric PML/RAR mRNA was detected by
nested RT-PCR in accordance with the primer
sequences and PCR conditions described by Borrow et
al.21 In order to define the type of chimeric PML/RAR
(bcr1, bcr2 or bcr3) detected, the M2 primer, as
reported by Lo Coco et al., was also used.22 In order to
screen the RAR or PML/RAR LBD mutations a 728
nt PCR product was obtained using oligonucleotide
E2 as the sense primer (5’-GCA TCA TTA AGA CTG
TGG AG-3’) and EF1a as the antisense primer (5’-GTA
GAA GGC AGA GAA AAG C-3’) in a 50 µL reaction
mixture containing 0.225 mmol/L dNTPs, 1 µmol/L of
each primer, 2.5 U of Taq polymerase (Roche Diag-
nostics, Mannheim, Germany), 1.5 mmol/L MgCl2, 10
mmol/L Tris-HCl, pH 8.3, 50 mmol/L KCl, 5%
dimethyl sulfoxide. The conditions of amplification
were: 1 minute at 94°C, 1 minute at 55°C and 1
minute at 72°C for 40 cycles with 2 minutes of an ini-
tial denaturation step at 94°C and 10 min of a final
extension step at 72°C. 
A sense primer corresponding to exon 1 of RAR
(RAR-1A primer: 5’-ATG GCC AGC AAC AGC AGC
TCC TGC CCG AC-3’) and to exon 3 of PML (PML
primer: 5’-TGT GCT GCA GCG CAT CCG CA-3’)
together with E4 antisense primer (5’-GCG AAG GCA
AAG ACC AGG-3’) were used in different PCR reac-
tions performed under the same conditions in order
to obtain differential amplification of the LBD of the
RAR and of the PML/RAR genes. Using the PML
oligonucleotide as the sense primer a fragment of 991
nt was obtained from patient #1; this represented the
bcr3 type of the PML/RAR mRNA. Two fragments
of 1,465 and 1,321 nt, representative of the
PML/RAR bcr1 type, were obtained from patient
#2. A fragment of 937 nt representative of the RAR
mRNA was obtained from the patients when primers
RAR-1A and E4 were used. Under the same condi-
tion, 2.5 µL of the PML-E4 and of the RAR-1A-E4
PCR reactions were re-amplified using E2 sense and
E4 antisense primers, obtaining a fragment of 234 nt
that was used for further sequencing analysis. 
RT-PCR fragments excised from 1% low-melting
agarose and further purified by Wizard PCR preps
DNA purification kit (Promega, Madison, WI, USA)
were directly sequenced using a BigDye terminator
cycle sequencing kit and a DNA sequencer (ABI Prism
310 - PE Applied Biosystem, Foster City, CA, USA).
Sequencing reactions were performed with the same
oligonucleotides as those used in PCR amplifications
by either the sense or antisense primers.
Clinical history
Patient #1
BP, a 30-year old man was diagnosed in December
1996 as having APL with the presence of a typical
PML-RAR chimeric mRNA of the short type (bcr3).
The patient was treated with idarubicin plus ATRA (45
mg/m2/d) and with Ara-C plus idarubicin or mitox-
antrone for three consolidation courses, according to
the Italian GIMEMA AIDA protocol.12 The patient
achieved complete clinical and molecular remission
and was treated with ATRA 45 mg/m2/d for 15 days
every three months as consolidation therapy; he
received three courses. Nine months after the end of
the consolidation therapy the patient clinically
relapsed and RT-PCR also revealed the presence of
PML/RAR chimeric mRNA. The patient was again
treated with ATRA and idarubicin according to the
AIDA protocol induction regimen, but without suc-
cess. Therefore, arsenic trioxide (As2O3) associated
with ATRA (45 mg/m2/d) was started at the dosage of
10 mg/d by i.v. infusion over 2 hours for 20 consecu-
tive days. The patient achieved complete clinical and
molecular remission. Further details about the clinical
course of this patient have already been published.23
Patient #2
AF, a 56 year-old man was diagnosed as having
APL in November 1996 by PB and BM morphologic
examination. Nested RT-PCR revealed the presence
of the long form (bcr1) PML/RAR chimeric mRNA.
The patient had thrombosis of the common iliac
artery as well a slowly-resolving staphylococcal pneu-
monia, so treatment with ATRA (45/m2/d) as a sin-
gle agent was started. The patient obtained a com-
plete clinical and hematologic, but not molecular
remission. ATRA administration was maintained
until the disease relapsed after 8 months. Induction
chemotherapy was started with idarubicin followed
by three consolidation courses with Ara-C plus idaru-
bicin or mitoxantrone in accordance with the AIDA
protocol,12 producing a second good clinical and
hematologic, but not molecular, remission. Two
months after the end of the consolidation therapy
(June 1998), a second relapse was evident and ATRA
therapy at the same standard dosage was started
again and maintained for a month without any sign
of clinical or hematologic response. The ATRA ther-
apy was, therefore, stopped and the patient treated
with As2O3 10 mg/d by i.v. infusion over two hours
for 42 days, achieving a third complete, but not mol-
ecular remission. 
Results
We screened for mutations of LBD PCR products
using different oligonucleotides as primers in the RT-
PCR experiments as shown in Figure 1. The different
amplicons obtained were analyzed by an unambigu-
ous bi-directional automatic direct sequencing analy-
sis. The E2-EF1a fragment of 728 nucleotides was ini-
tially obtained from BM specimens taken during
patient #1’s APL first relapse and patient #2’s second
relapse. This PCR fragment is representative of the
complete LBD of both PML/RAR and normal RAR
genes. Patient #1’s specimen revealed the presence of
a G to A missense mutation at position 917, accord-
ing to the nucleotide sequence of the RAR gene (ref-
erence sequence, Giguere et al.24). This mutation leads
to the replacement of an arginine (Arg) amino acid by
glutamine (Gln), corresponding to RAR codon 272.
The same mutation has already been reported by
Imaizumi et al. in an APL patient.17 Patient #2’s spec-
imen revealed an as yet unreported mutation in which
a T replaces a C at position 928, leading to the sub-
stitution of an arginine (Arg) by tryptophan (Trp) at
codon 276. The same analysis was performed on spec-
imens from both patients at the onset of APL,  when
no nucleotide substitutions were found. In order to
confirm the presence of the mutations and to distin-
guish in which gene, either RAR or PML/RAR, the
point mutations were present, we performed differen-
tial amplifications of the PML/RAR and RAR genes,
using as sense primers, the RAR-1A oligonucleotide
specific to the RAR gene and the PML oligonu-
cleotide specific to the PML/RAR gene in two differ-
ent PCR reactions, using as antisense primer the E4
oligonucleotide. Both reactions were re-amplified
using E2 and E4 primers. Sequence analysis revealed
the presence of the missense mutations in the
PML/RAR derived amplicons from both patients.
The normal RAR derived amplicons were unmutat-
ed (Figure 2). Other BM specimens taken from patient
#2 throughout the course of the disease were avail-
able, allowing the timing of the appearance of the mis-
sense mutations to be studied. The C928T mutation
was absent in the BM specimens collected 2 and 5
months after the onset of APL and first appeared in
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Figure 1: Schematic representation of the PML/RAR
(upper) and RAR (lower) cDNAs. The PML portion is
hatched, the RAR coding regions are grey and the RAR
untranslated regions are clear. Numbered boxes are PML
and RAR exons. The upper vertical arrows indicate the
three breakpoint sites (bcr1, bcr2, bcr3) of the PML gene
involved in the PML/RAR translocation. Arrowheads indi-
cate the site of the primers used for PCR and sequencing
analysis. Position and the type of the missense mutations
in the PML/RAR ligand binding domain (LBD) found in the
patients examined are also indicated. 
Figure 2. Automated sequencing analysis of the PCR prod-
ucts derived from the ligand binding domain of the RAR (A)
and of the PML/RAR (B) of the patients with APL exam-
ined  during ATRA-resistant relapse. Vertical arrows indi-
cate the normal RAR nucleotides and the correspondent
mutated PML/RAR nucleotides.
the BM specimen collected 8 months  after the onset
of APL. This was the time of the patient’s first relapse.
The mutation was present in all subsequent BM sam-
ples. 
Discussion
ATRA treatment of APL induces terminal cell dif-
ferentiation and complete clinical remission. Never-
theless, these remissions are transient and ATRA-
resistance often appears at relapse. There are differ-
ent mechanisms underlying this acquired resistance:
during continuous administration, ATRA plasma
concentrations decrease as a result of enhanced
activity of P450 as well as up-regulation of the
CRABP protein.25,26 Nevertheless, ATRA-resistance is
also present at a cellular level. Several laboratories
have identified ATRA-resistant sub-clones of the NB4
cell lines. Of interest, in the retinoic-resistant NB4-R4
subclone, Shao et al. identified a missense mutation
in the LBD of the RAR portion of the PML/RAR
but not of the RAR gene.16 This mutation abrogates
the ability of the PML/RAR protein to bind its lig-
and inhibiting, in a retinoic-independent dominant-
negative manner, the co-expressed wild-type RAR.
Very recently, Imaizumi et al. and Ding et al. indepen-
dently reported the presence of point missense muta-
tions in the LBD of the PML/RAR gene in 5 ATRA-
resistant relapsed patients, in particular in those
patients who had received prolonged or intermittent
administration of ATRA before relapse.17,18
In this study we identified two new ATRA-resistant
APL patients with a mutated PML/RAR. The muta-
tions were present only at relapse, and were not
detected at the onset of APL in either patient exam-
ined. Moreover, analysis of different BM specimens
from patient #2 indicates that the appearance of the
mutation is strictly related to APL relapse, since ear-
ly BM samples collected during remission did not
contain mutations, but were still positive for
PML/RAR chimeric mRNA by RT-PCR. These data
strongly suggest that APL LBD-mutated cells may
have a significant proliferative and survival advantage
over APL LBD-wild-type cells during the course of
ATRA therapy, so that their clonal expansion may
give rise to clinical relapse. 
The missense mutations found in the two patients
examined are both in the 5’ portion of the LBD. In
particular, Arg272 of RAR appears to be very impor-
tant in making van der Waal contact with the acyl-
chain of ATRA.27 In fact, site direct mutagenesis at
Arg272 is able to impair the ATRA binding capacity
of RAR.28 Therefore, the Arg272Gln mutation found
in patient #1, already reported by Imaizumi et al.,17
seems to play a crucial role in the ligand function of
RAR. This alteration probably causes the clinical
ATRA-resistance shown in this patient. In patient #2
an as yet unreported Arg276Trp substitution, close-
ly related to Arg272, was observed. In this case too
the involved amino acid residue seems to play a cru-
cial role in ligand binding capacity of RAR, making
a weak salt bridge with the retinoic acid carboxylate.
It also contributes to the inter-aminoacidic hydro-
gen-bound network of the LBD RAR region.26
In 1997 investigators from China reported that
As2O3 was able to induce complete remission in APL
relapsed patients.29 These data have been very recent-
ly confirmed by Soignet et al.30 Both patients reported
here clearly demonstrated clinical resistance to ATRA
and cytotoxic chemotherapy. We therefore decided to
treat them with As2O3, which induced complete remis-
sion in both the patients without significant toxic side
effects. A recent report by Nason-Burchenal et al.
revealed that reduction of PML/RAR expression in
the NB4-R1 ATRA resistant APL cell line, bearing a
mutation in the LBD of the PML/RAR, is incompat-
ible with leukemic cell growth.31 Therefore targeting
PML/RAR could have therapeutic potential in
retinoic-resistant APL cells. This might be the advan-
tage of arsenic trioxide which is able to induce partial
differentiation and apoptosis of APL cell lines with
wild-type or LBD mutated PML/RAR, inducing rapid
degradation of the chimeric protein.32,33 Further in vivo
and in vitro molecular studies are necessary in order to
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Figure 3. Summary of the LBD PML/RAR mutations so far
associated with ATRA-resistance. The ligand binding
domain (LBD) comprised between nucleotide #700 and
#1359, according to the nucleotide number assignment by
Giguere et al.24 is represented. Arrows with numbers indi-
cate the site of point mutations in APL patients (1-5) and
cell lines (6,7). 1: G917A (Arg272Gln) and 2: A991T
(Met297Leu) reported by Imaizumi et al.17 3: T1340C
(Met413Thr), 4: C970G (Leu290Val) and 5: C1282T
(Arg392Trp) reported by Ding et al.18 6: C1322T
(Pro407Leu) reported by Kitamura et al.34). 7: T1295C
(Leu398Pro) reported by Shao et al.32 White arrowheads
indicate the sites of the two point mutations reported in this
paper.
define whether the retinoic acid binding capacity is in
fact affected in all the LBD mutated cases and whether
degradation of the PML/RAR protein still occurs dur-
ing As2O3 treatment. The two cases reported here pro-
vide the first in vivo evidence that APL cells bearing LBD
point mutations  are sensitive to As2O3, indicating that
this apoptotic agent may have a use in APL patients
who become ATRA resistant for molecular reason. 
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